Cardiac metastases are malignant tumors that spread secondarily to the heart and are 20-40 times more common than primary cardiac tumors. The most frequent sources are lung carcinoma (36-39%), breast carcinoma (10-12%), melanoma (5-7%, with the highest tropism rate — cardiac involvement is found in 50-65% of melanoma patients at autopsy), lymphoma/leukemia (10-15%), and renal cell carcinoma. Spread pathways include hematogenous (most common), lymphatic (pericardial involvement), direct invasion (lung, esophagus, mediastinal tumors), and intracavitary extension (renal cell carcinoma → IVC → right atrium, hepatocellular carcinoma). The pericardium is the most frequently involved structure (64-69%), followed by myocardium (25-30%) and endocardium (3-5%). Clinical presentation is usually asymptomatic; symptomatic cases may present with pericardial effusion (30-50% — tamponade risk), arrhythmia, heart failure, embolization, and sudden death. Diagnosis is typically made on imaging in patients with known primary malignancy. Prognosis is poor — median survival is 3-12 months and treatment is generally palliative.
Age Range
40-80
Peak Age
60
Gender
Equal
Prevalence
Uncommon
The pathogenesis of cardiac metastases involves four main dissemination mechanisms. (1) Hematogenous spread is the most common route — malignant cells reach the myocardium via coronary arteries or bronchial arteries. Melanoma's cardiac tropism is explained by the high affinity of melanoma cells for endothelial adhesion molecules (ICAM-1, VCAM-1), which are abundant in cardiac endothelium. (2) Lymphatic spread is particularly prominent in pericardial involvement — the pericardium is involved through retrograde lymphatic flow from mediastinal lymph nodes, leading to hemorrhagic pericardial effusion. The high protein content and hemorrhagic nature of the effusion relates to tumor invasion of pericardial mesothelial cells and increased vascular permeability. (3) Direct invasion occurs as direct pericardial and myocardial invasion by lung carcinoma, esophageal carcinoma, or mediastinal masses. (4) Intracavitary extension — renal cell carcinoma classically extends through renal vein → IVC → right atrium; hepatocellular carcinoma similarly follows hepatic veins → IVC → right atrium. Basis of imaging findings: myocardial metastases cause focal or diffuse myocardial thickening and show heterogeneous post-contrast enhancement — related to irregular tumor neovascularization and necrosis areas. Pericardial effusion results from tumor invasion of the pericardial surface and increased capillary permeability. Multiple lesions are a characteristic finding of metastasis and the most important clue for differentiation from primary tumors.
Detection of multiple cardiac masses with heterogeneous LGE and accompanying pericardial effusion in a patient with known primary malignancy history is considered practically diagnostic of cardiac metastasis. Primary cardiac tumors are typically solitary and 20-40 times rarer than metastases. When this triad (multiple masses + effusion + malignancy history) is present, metastasis diagnosis can be made without even requiring biopsy.
On T1-weighted images, most cardiac metastases appear iso- or slightly hypointense relative to myocardial signal. An important exception is melanoma metastasis — it shows characteristic T1 hyperintensity due to melanin content (paramagnetic effect). T1 hyperintensity is seen in 50-70% of metastatic melanoma cases and carries significant diagnostic value. Hemorrhagic metastases may also show T1 hyperintensity due to subacute hemorrhage (methemoglobin). When pericardial effusion is present, hemorrhagic effusion is brighter on T1 than serous effusion.
Report Sentence
On cardiac MR T1-weighted images, a mass/masses of ___ intensity compared to myocardium is/are seen at ___ location, findings consistent with metastatic involvement.
On T2-weighted images, cardiac metastases typically show heterogeneous, intermediate-to-high signal. The cellularity of solid tumor gives intermediate T2 signal, while necrotic/cystic areas appear markedly hyperintense. Metastatic melanoma shows variable T2 signal — paradoxical T2 hypointensity may be seen due to melanin content (in 30% of cases). Pericardial effusion is markedly hyperintense on T2, and accompanying pericardial nodules/thickening indicate metastatic involvement. On STIR sequences, lesions appear bright and are well distinguished from myocardium.
Report Sentence
On T2-weighted images, heterogeneously signaling mass(es) measuring ___ are seen, with necrotic areas appearing hyperintense.
Late gadolinium enhancement (LGE) plays a critical role in evaluating cardiac metastases. Metastases typically show heterogeneous LGE pattern — viable tumor tissue enhances while necrotic areas do not. This pattern differs from the total absence of enhancement in cardiac thrombus (the most important finding in thrombus vs tumor differentiation). In pericardial metastases, nodular or diffuse pericardial enhancement is seen. Diffuse delayed enhancement may be observed in areas of myocardial infiltration, which can resemble myocarditis. The presence of multiple lesions with heterogeneous LGE strongly supports metastasis.
Report Sentence
On late gadolinium enhancement images, the mass(es) at ___ location show heterogeneous enhancement with non-enhancing central necrotic areas; findings are consistent with cardiac metastasis.
On contrast-enhanced CT, cardiac metastases appear as single or multiple masses with heterogeneous enhancement in arterial/portal venous phases. Myocardial lesions may be seen as focal thickening or space-occupying masses. Pericardial effusion frequently accompanies (30-50%) and effusion attenuation may be higher than simple fluid density (>20 HU) due to hemorrhagic content. Pericardial nodularity and thickening are additional findings. CT's greatest advantage is the simultaneous evaluation of the primary tumor and other organ metastases. Motion artifacts may reduce diagnostic power if ECG-gated CT is not performed.
Report Sentence
On contrast-enhanced CT, ___ cardiac mass(es) showing heterogeneous enhancement at ___ location is/are seen, accompanied by pericardial effusion; findings are consistent with cardiac metastasis in the setting of known ___ malignancy.
On echocardiography, cardiac metastases appear as intracardiac mass or myocardial thickening. Transthoracic echocardiography (TTE) is typically the initial diagnostic tool — it can detect 75-80% of cardiac masses. Lesions are usually visualized as masses adherent to the myocardium, iso- or slightly hyperechoic, disrupting wall motion. Pericardial effusion is a common accompanying finding — effusion may be anechoic (serous) or contain internal echoes (hemorrhagic/exudative). Tamponade signs (right ventricular diastolic collapse, right atrial systolic inversion, respiratory variation) should be evaluated. Transesophageal echocardiography (TEE) provides higher resolution particularly for left atrial appendage and small pericardial nodules.
Report Sentence
On echocardiography, an intracardiac mass measuring ___ cm at ___ location is seen, related to the myocardium, accompanied by ___ amount of pericardial effusion.
On FDG PET-CT, cardiac metastases typically show increased FDG uptake. Cardiac involvement may be detected during staging or treatment response assessment of the primary tumor. In pericardial metastases, diffuse or nodular pericardial FDG activity is observed. Physiologic FDG uptake in normal myocardium is variable and may complicate detection of myocardial metastases — prolonged fasting (>12 hours) or high-fat diet suppresses myocardial FDG uptake to improve lesion detection. PET-CT's advantage is whole-body scanning for detection of concurrent metastases and treatment response evaluation.
Report Sentence
On FDG PET-CT, cardiac lesion(s) showing increased FDG uptake with SUVmax of ___ at ___ location is/are seen, consistent with metastatic involvement.
Criteria
Focal or multifocal mass/thickening in myocardial tissue; most commonly seen with hematogenous spread
Distinct Features
Wall motion abnormality, arrhythmia risk, heterogeneous enhancement, LGE positive — wide spectrum from mass distinguishable from myocardium to large infiltrative lesion on MR
Criteria
Pericardial involvement: nodularity, thickening, effusion; most common with lymphatic or direct spread
Distinct Features
Hemorrhagic pericardial effusion (CT >20 HU, MR T1 hyperintense), pericardial nodules or diffuse thickening, tamponade risk — pericardial involvement most common in lung and breast carcinoma
Criteria
Tumor extending to cardiac chambers via venous system; typically IVC → right atrium pathway
Distinct Features
Renal cell carcinoma (renal vein → IVC → right atrium), hepatocellular carcinoma (hepatic vein → IVC → right atrium), adrenocortical carcinoma — enhancing mass can be traced within IVC, enhances unlike bland thrombus
Criteria
Mass growing from endocardial surface into the lumen; rarest form (3-5%)
Distinct Features
Most easily confused with thrombus — LGE enhancement distinguishes from thrombus; high embolization risk; relatively more common in melanoma and sarcomas
Distinguishing Feature
Cardiac thrombus shows no enhancement on LGE (avascular) — metastasis shows heterogeneous enhancement. Thrombus is usually attached to akinetic/dyskinetic wall and is solitary, while metastases are often multiple.
Distinguishing Feature
Myxoma is typically a solitary, homogeneous mass in the left atrium attached to the interatrial septum by a stalk. Shows marked T2 hyperintensity and homogeneous LGE enhancement. Metastases are multiple, heterogeneous, and in different locations.
Distinguishing Feature
Primary cardiac lymphoma usually shows diffuse infiltrative growth in the right atrium, accompanied by pericardial effusion. Shows intermediate T2 signal and homogeneous enhancement. Clinical context (absence of known malignancy, immunosuppression) and lesion morphology (infiltrative vs nodular) help differentiation from metastasis.
Distinguishing Feature
Angiosarcoma is the most common primary cardiac malignancy and appears as an aggressive, hemorrhagic mass in the right atrium. Shows T1 hyperintense signal (hemorrhage) and heterogeneous enhancement. Absence of primary malignancy history, solitary lesion, and prominent hemorrhagic component help differentiation from metastasis.
Urgency
urgentManagement
medicalBiopsy
Not NeededFollow-up
specialist-referralWhen cardiac metastasis is diagnosed, multidisciplinary evaluation with oncology and cardiology teams is required. Treatment is generally directed toward the primary tumor — systemic chemotherapy, immunotherapy, or targeted therapy. If there is tamponade risk with pericardial effusion, emergent pericardiocentesis is performed — recurrent effusion may require pericardial window or catheter drainage. Surgical resection is rarely performed — may be considered for solitary metastases or lesions causing hemodynamic compromise. Radiation therapy may be used palliatively for pericardial or myocardial involvement. Prognosis is related to the type and stage of the primary tumor — median survival is 3-12 months. Biopsy is generally not needed as known malignancy history and typical imaging findings are sufficient for diagnosis.
Detection of cardiac metastasis indicates advanced-stage disease with generally poor prognosis. Pericardial tamponade may require emergent pericardiocentesis. Arrhythmia, embolization, and obstructive symptoms can be life-threatening. Treatment is systemic therapy directed at the primary tumor; surgery is rarely indicated. Melanoma and lymphoma metastases may respond to chemotherapy.